AstraZeneca provides Update on GALATHEA Phase III Trial for Fasenra in Chronic Obstructive Pulmonary Disease

Fasenra is AstraZeneca’s first respiratory biologic and is currently approved as an add-on treatment for severe eosinophilic asthma in the US, EU, Japan and several other countries.

News Reference:

Share: